Entrada Therapeutics Share Price Today
(NASDAQ: TRDA)

Name: Entrada Therapeutics Share Price Today (NASDAQ: TRDA) - Entrada Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Entrada Therapeutics share price is $13.33 & ₹1,161.04 as on 4 Feb 2025, 2.30 'hrs' IST

$13.33

▲

-0.11

(-0.82%)

Market is closed - opens 8 PM, 04 Feb 2025

View live Entrada Therapeutics share price in Dollar and Rupees. Guide to invest in Entrada Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Entrada Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Entrada Therapeutics share price movements

Today's Low: $12.53
Today's High: $13.62
$13.33
6.0%
Downside
Day's Volatility :8.0%
Upside
2.13%
52 Weeks Low: $11.35
52 Weeks High: $21.79
$13.33
14.85%
Downside
52 Weeks Volatility :47.91%
Upside
38.83%

Entrada Therapeutics (TRDA) Returns

Period	Entrada Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-28.41%	0.5%	0.0%
6 Months	-9.26%	-2.3%	0.0%
1 Year	-6.91%	3.8%	0.0%
3 Years	33.17%	11.4%	-11.7%

Entrada Therapeutics (TRDA) Key Statistics

in dollars & INR

Previous Close	$13.44
Open	$12.85
Today's High	$13.62
Today's Low	$12.53
Market Capitalization	$502.9M
Today's Volume	$104.0K
52 Week High	$21.79
52 Week Low	$11.35
Revenue TTM	$215.2M
EBITDA	$61.3M
Earnings Per Share (EPS)	$1.44
PE Ratio	9.33
Profit Margin	25.53%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	16.42%

How to invest in Entrada Therapeutics Stock (TRDA) from India?

It is very easy for Indian residents to invest directly in Entrada Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Entrada Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Entrada Therapeutics or TRDA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Entrada Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Entrada Therapeutics shares which would translate to 0.065 fractional shares of Entrada Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Entrada Therapeutics, in just a few clicks!

Returns in Entrada Therapeutics (TRDA) for Indian investors in Rupees

The Entrada Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Entrada Therapeutics investment value today

Current value as on today

₹97,957

Returns

₹2,043

(-2.04%)

Returns from Entrada Therapeutics Stock

₹6,913 (-6.91%)

Dollar Returns

₹4,871 (+4.87%)

Indian investors sentiment towards Entrada Therapeutics (TRDA)

-33%

Period: Jan 4, 2025 to Feb 3, 2025. Change in 30 Days versus previous period

Search interest for Entrada Therapeutics Stock from India on INDmoney has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Entrada Therapeutics

Baker Bros Advisors LP
13.00%
Mpm Asset Management, LLC
11.83%
5AM Venture Management, LLC
11.78%
T. Rowe Price Associates, Inc.
8.15%
BlackRock Inc
4.87%
FMR Inc
4.66%

Analyst Recommendation on Entrada Therapeutics

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Entrada Therapeutics(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Entrada Therapeutics Stock (TRDA)

What analysts predicted

Upside of 98.26%

Target:

$26.43

Current:

$13.33

Insights on Entrada Therapeutics Stock (Ticker Symbol: TRDA)

Price Movement
In the last 1 month, TRDA stock has moved down by -27.2%
TRDA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 58.6% return, outperforming this stock by 68.0%
TRDA vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 88.8% return, outperforming this stock by 58.5%
Price to Sales
ForTRDA every $1 of sales, investors are willing to pay $2.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.6 for every $1 of sales.

Entrada Therapeutics Technicals Summary

Sell

Neutral

Buy

Entrada Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Entrada Therapeutics (TRDA) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Entrada Therapeutics, Inc.	-26.15%	-9.26%	-6.91%	33.17%	-44.34%
Biontech Se	-0.32%	50.72%	28.36%	-30.66%	263.86%
Regeneron Pharmaceuticals, Inc.	-6.9%	-37.45%	-28.78%	7.15%	71.05%
Vertex Pharmaceuticals Incorporated	16.87%	-0.83%	9.67%	93.36%	96.71%
Alnylam Pharmaceuticals, Inc.	17.76%	4.57%	60.84%	84.7%	125.11%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Entrada Therapeutics, Inc.	9.33	9.33	NA	1.07	0.16	0.07	NA	11.93
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.64	16.64	1.08	44.92	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Entrada Therapeutics, Inc.	Buy	$502.9M	-44.34%	9.33	25.53%
Biontech Se	Buy	$29.7B	263.86%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$74.0B	71.05%	16.64	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$118.9B	96.71%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.0B	125.11%	NA	-15.86%

About Entrada Therapeutics

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Organization	Entrada Therapeutics
Employees	177
CEO	Mr. Dipal Doshi
Industry	Services

Management People of Entrada Therapeutics

Name	Title
Mr. Dipal Doshi	CEO & Director
Mr. Nathan J. Dowden	President & COO
Dr. Natarajan Sethuraman Ph.D.	President of Research & Development
Mr. Kory James Wentworth CPA	CFO & Treasurer
Dr. Jared Cohen J.D., Ph.D.	General Counsel
Ms. Kerry Robert M.S.	Senior Vice President of People
Ms. Karla MacDonald	Chief Corporate Affairs Officer
Mr. Kevin Healy Ph.D.	Senior Vice President of Regulatory Affairs

Important FAQs about investing in TRDA Stock from India :

What is Entrada Therapeutics share price today?

Entrada Therapeutics share price today stands at $13.33, Open: $12.85 ; Previous Close: $13.44 ; High: $13.62 ; Low: $12.53 ; 52 Week High: $21.79 ; 52 Week Low: $11.35.

The stock opens at $12.85, after a previous close of $13.44. The stock reached a daily high of $13.62 and a low of $12.53, with a 52-week high of $21.79 and a 52-week low of $11.35.

Can Indians buy Entrada Therapeutics shares?

Yes, Indians can invest in the Entrada Therapeutics (TRDA) from India.

With INDmoney, you can buy Entrada Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Entrada Therapeutics at zero transaction cost.

How can I buy Entrada Therapeutics shares from India?

It is very easy to buy Entrada Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Entrada Therapeutics (TRDA) be purchased?

Yes, you can buy fractional shares of Entrada Therapeutics with INDmoney app.

What are the documents required to start investing in Entrada Therapeutics stocks?

To start investing in Entrada Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.